These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

345 related items for PubMed ID: 15969893

  • 1. Long-acting blood pressure reduction by candesartan cilexetil in patients with hypertension.
    Bönner G, Fuchs W.
    Curr Med Res Opin; 2005 Jun; 21(6):935-40. PubMed ID: 15969893
    [Abstract] [Full Text] [Related]

  • 2. Candesartan cilexetil: an angiotensin II receptor blocker.
    Stoukides CA, McVoy HJ, Kaul AF.
    Ann Pharmacother; 1999 Dec; 33(12):1287-98. PubMed ID: 10630830
    [Abstract] [Full Text] [Related]

  • 3. Candesartan cilexetil: in children and adolescents aged 1 to <17 years with hypertension.
    Hoy SM, Keating GM.
    Am J Cardiovasc Drugs; 2010 Dec; 10(5):335-42. PubMed ID: 20860416
    [Abstract] [Full Text] [Related]

  • 4. Candesartan cilexetil: a new, long-acting, effective angiotensin II type 1 receptor blocker.
    Sever P.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S91-5. PubMed ID: 9331018
    [Abstract] [Full Text] [Related]

  • 5. Candesartan cilexetil: a review of its preclinical pharmacology.
    Nishikawa K, Naka T, Chatani F, Yoshimura Y.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S9-17. PubMed ID: 9330999
    [Abstract] [Full Text] [Related]

  • 6. Achieving quality 24-h blood pressure control with candesartan cilexetil.
    Meredith P.
    Blood Press Suppl; 2000 Sep; 1():23-6. PubMed ID: 11059632
    [Abstract] [Full Text] [Related]

  • 7. Pharmacokinetics of candesartan after single and repeated doses of candesartan cilexetil in young and elderly healthy volunteers.
    Hübner R, Högemann AM, Sunzel M, Riddell JG.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S19-25. PubMed ID: 9331000
    [Abstract] [Full Text] [Related]

  • 8. Acute effects of candesartan cilexetil (the new angiotensin II antagonist) on systemic and renal haemodynamics in hypertensive patients.
    Fridman K, Andersson OK, Wysocki M, Friberg P, Sunzel M.
    Eur J Clin Pharmacol; 1998 Sep; 54(7):497-501. PubMed ID: 9832289
    [Abstract] [Full Text] [Related]

  • 9. Twenty-four hour blood pressure profile of different doses of candesartan cilexetil in patients with mild to moderate hypertension.
    Heuer HJ, Schöndorfer G, Högemann AM.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S55-6. PubMed ID: 9331008
    [No Abstract] [Full Text] [Related]

  • 10. The efficacy and tolerability of candesartan cilexetil in an elderly hypertensive population.
    McInnes GT, O'Kane KP, Jonker J, Roth J.
    J Hum Hypertens; 1997 Sep; 11 Suppl 2():S75-80. PubMed ID: 9331015
    [Abstract] [Full Text] [Related]

  • 11. [Change from ACE inhibitor, Ca-antagonist or beta-blocker to candesartan cilexetil: better efficacy and tolerance. SWITCH study (German study segment)].
    Baumgart P, Reismann J, Pohlmeyer H, Düsing R.
    Dtsch Med Wochenschr; 2001 May 11; 126(19):547-50. PubMed ID: 11402910
    [Abstract] [Full Text] [Related]

  • 12. Efficacy, safety and pharmacokinetics of candesartan cilexetil in hypertensive children from 1 to less than 6 years of age.
    Schaefer F, van de Walle J, Zurowska A, Gimpel C, van Hoeck K, Drozdz D, Montini G, Bagdasorova IV, Sorof J, Sugg J, Teng R, Hainer JW, Candesartan in Children with Hypertension Investigators.
    J Hypertens; 2010 May 11; 28(5):1083-90. PubMed ID: 20160654
    [Abstract] [Full Text] [Related]

  • 13. A placebo-controlled comparison of the efficacy and tolerability of candesartan cilexetil, 8 mg, and losartan, 50 mg, as monotherapy in patients with essential hypertension, using 36-h ambulatory blood pressure monitoring.
    Baguet JP, Nisse-Durgeat S, Mouret S, Asmar R, Mallion JM.
    Int J Clin Pract; 2006 Apr 11; 60(4):391-8. PubMed ID: 16620350
    [Abstract] [Full Text] [Related]

  • 14. Candesartan cilexetil: an angiotensin II-receptor blocker.
    See S, Stirling AL.
    Am J Health Syst Pharm; 2000 Apr 15; 57(8):739-46. PubMed ID: 10786259
    [Abstract] [Full Text] [Related]

  • 15. Efficacy and safety of 10-mg azilsartan compared with 8-mg candesartan cilexetil in Japanese patients with hypertension: a randomized crossover non-inferiority trial.
    Takahara M, Shiraiwa T, Shindo M, Arai A, Kusuda Y, Katakami N, Kaneto H, Matsuoka TA, Shimomura I.
    Hypertens Res; 2014 Sep 15; 37(9):852-7. PubMed ID: 24739538
    [Abstract] [Full Text] [Related]

  • 16. Improving antihypertensive efficacy while maintaining placebo-like tolerability.
    Sever PS.
    Blood Press Suppl; 2000 Sep 15; 1():19-22. PubMed ID: 11059631
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and tolerability of candesartan cilexetil in special patient groups.
    Trenkwalder P.
    Blood Press Suppl; 2000 Sep 15; 1():27-30. PubMed ID: 11059633
    [Abstract] [Full Text] [Related]

  • 18. Candesartan cilexetil, a new generation angiotensin II antagonist, provides dose dependent antihypertensive effect.
    Elmfeldt D, George M, Hübner R, Olofsson B.
    J Hum Hypertens; 1997 Sep 15; 11 Suppl 2():S49-53. PubMed ID: 9331007
    [Abstract] [Full Text] [Related]

  • 19. Pharmacologic properties of candesartan cilexetil--possible mechanisms of long-acting antihypertensive action.
    Inada Y, Ojima M, Kanagawa R, Misumi Y, Nishikawa K, Naka T.
    J Hum Hypertens; 1999 Jan 15; 13 Suppl 1():S75-80. PubMed ID: 10076925
    [Abstract] [Full Text] [Related]

  • 20. Evaluation of the effect of candesartan cilexetil on the steady-state pharmacokinetics of tacrolimus in renal transplant patients.
    Pietruck F, Kiel G, Birkel M, Stahlheber-Dilg B, Philipp T.
    Biopharm Drug Dispos; 2005 May 15; 26(4):135-41. PubMed ID: 15768377
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 18.